Q-omics provides the consensus-scored CABCOCO1 profile across patient tissues and cancer cell-line models. CABCOCO1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CABCOCO1 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, CABCOCO1 RNA expression shows 15,645 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight BRCA, KICH, and LUAD as cancer lineages where CABCOCO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CABCOCO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CABCOCO1 survival associations across molecular data types. CABCOCO1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CABCOCO1 RNA expression–survival associations across cancer types. High CABCOCO1 expression shows unfavorable associations in STAD and UCEC, but favorable associations in BRCA, UVM, KIRP and KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for CABCOCO1 RNA expression.
This table summarizes CABCOCO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CABCOCO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CABCOCO1 shows lower tumor expression in KICH, LUAD, THCA, BLCA, COAD and LUSC. The KICH box plot shows higher CABCOCO1 RNA expression in normal versus tumor tissue (log2 FC = −2.460, t-test p < 0.001).
This table shows molecular features associated with CABCOCO1 in patient tissues and cancer cell lines. In patient samples, CABCOCO1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CABCOCO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and CNS.
